Author Correction: AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 mice
In the version of the article initially published, a reference citation was missing in the first sentence of the Results "Translatability to human targets" section, which now reads "To determine the ability of miAtxn2 to target human ATXN2, we used the 127Q transgenic mouse model of spinocerebellar ataxia type 2, in which mice overexpress mutant human ATXN2 in cerebellar Purkinje cells [Hansen, S.
Authors
- Joshua A. Fuller
- Aleksandar Izda
- Congsheng Cheng
- Ashley B. Robbins (ORCID: https://orcid.org/0000-0002-6675-1603)
- Shareen Nelson
- Defne A. Amado (ORCID: https://orcid.org/0000-0001-6202-3900)
- Beverly L. Davidson (ORCID: https://orcid.org/0000-0002-3715-6290)
- Alex Mas Monteys (ORCID: https://orcid.org/0000-0003-2539-8468)
- Esteban O. Mazzoni (ORCID: https://orcid.org/0000-0001-8994-681X)
- Yonghong Chen (ORCID: https://orcid.org/0000-0001-9552-1308)
- Alicia R. Smith (ORCID: https://orcid.org/0000-0001-7635-8461)
- Abigail I. Dichter
- Katherine R. Whiteman
- Guillem Chillon (ORCID: https://orcid.org/0000-0003-2750-9037)
- Nicholas A. Patty
Institutions
- Children's Hospital of Philadelphia (US)
- New York University (US)
- University of Pennsylvania (US)
- Philadelphia University (US)
Publication Details
- Journal
- Nature Communications
- Published
- 2025-10-23
- DOI
- https://doi.org/10.1038/s41467-025-65424-5
- Citations
- 1
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 1.82